Cerus Corporation is a global biomedical products company dedicated to safeguarding the world's blood supply through its proprietary pathogen reduction technology. The company's core offering is the INTERCEPT Blood System, which is designed to inactivate a broad range of blood-borne pathogens—including viruses, bacteria, and parasites—in donated blood components intended for transfusion. The system utilizes amotosalen and ultraviolet A (UVA) light to cross-link and prevent the replication of nucleic acids in pathogens and white blood cells, while preserving the therapeutic properties of platelets and plasma.
Cerus generates the vast majority of its revenue from the sale of disposable kits used in the INTERCEPT system, alongside its LED-based illuminator devices. For example, in the first quarter of 2026, product revenue accounted for approximately 90% of total revenue, with the remainder coming from government contracts and grants, such as those from BARDA and the Department of Defense, which fund the development of next-generation technologies. Its product portfolio includes the INTERCEPT Blood System for platelets and plasma, which holds both CE mark and FDA approval, and the INTERCEPT Fibrinogen Complex (IFC) for treating massive hemorrhage associated with fibrinogen deficiency. Additionally, Cerus is advancing its INTERCEPT system for red blood cells through late-stage clinical development. The company operates globally, selling its products through a direct sales force and distributors across the United States, Europe, the Middle East, Latin America, and other international markets.
